Your browser doesn't support javascript.
loading
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Martin, Thomas; Lin, Yi; Agha, Mounzer; Cohen, Adam D; Htut, Myo; Stewart, A Keith; Hari, Parameswaran; Berdeja, Jesus G; Usmani, Saad Z; Yeh, Tzu-Min; Olyslager, Yunsi; Goldberg, Jenna D; Schecter, Jordan M; Madduri, Deepu; Jackson, Carolyn C; Deraedt, William; Gries, Katharine S; Fastenau, John M; Trudeau, Jeremiah J; Akram, Muhammad; Pacaud, Lida; Jakubowiak, Andrzej; Jagannath, Sundar.
Afiliación
  • Martin T; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Lin Y; Mayo Clinic, Rochester, MN, USA.
  • Agha M; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
  • Cohen AD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Htut M; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Stewart AK; University Health Network and the Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Hari P; Medical College of Wisconsin, Milwaukee, WI, USA.
  • Berdeja JG; Sarah Cannon Research Institute, Nashville, TN, USA.
  • Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yeh TM; Janssen Research & Development, Raritan, NJ, USA.
  • Olyslager Y; Janssen Research & Development, Beerse, Belgium.
  • Goldberg JD; Janssen Research & Development, Raritan, NJ, USA.
  • Schecter JM; Janssen Research & Development, Raritan, NJ, USA.
  • Madduri D; Janssen Research & Development, Raritan, NJ, USA.
  • Jackson CC; Janssen Research & Development, Raritan, NJ, USA.
  • Deraedt W; Janssen Research & Development, Beerse, Belgium.
  • Gries KS; Janssen Research & Development, Raritan, NJ, USA.
  • Fastenau JM; Janssen Research & Development, Raritan, NJ, USA.
  • Trudeau JJ; Janssen Research & Development, Raritan, NJ, USA.
  • Akram M; Legend Biotech USA, Piscataway, NJ, USA.
  • Pacaud L; Legend Biotech USA, Piscataway, NJ, USA.
  • Jakubowiak A; University of Chicago, Chicago, IL, USA.
  • Jagannath S; Mount Sinai Medical Center, New York, NY, USA. Electronic address: sundar.jagannath@mountsinai.com.
Lancet Haematol ; 9(12): e897-e905, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36215989
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido